U.S. drugmaker Eli Lilly reported lower-than-expected quarterly revenue as it was hurt by disappointing sales of its cancer and diabetes drugs.» Read More
Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.
U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.
Biotech has been so hot the past two years that the sector is starting to raise red flags.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Biogen CEO George Scangos talks about future growth opportunities at the company on CNBC's "Fast Money."
MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.
Arkansas Supreme Court overturns $1.2 billion judgment against Johnson & Johnson over drug marketing.
Dr. Richard Saul wrote a book called "ADHD Does Not Exist." Saul is certain attention ADHD, or attention deficit hyperactivity disorder exists only in its symptoms. The condition does not exist.
CNBC's Sheila Dharmarajan reports 15 percent of high school aged children are diagnosed with ADHD, or attention deficit hyperactivity disorder.
Pfizer said a court had invalidated a key patent behind its blockbuster Celebrex drug, and plans to appeal the judgement.
A drug company worker accusing his employer of encouraging excessive dosage in heartburn medications faces a last-ditch U.S. Supreme Court bid.
Ranbaxy Laboratories issued a recall of generic versions of the cholesterol drug Lipitor in the U.S. because of potential dosage issues, WSJ reported.
Pfizer is in clinical trials to create an over-the-counter version of cholesterol drug, Lipitor. Barbara Ryan, FTI Consulting, discusses challenges the pharmaceutical will face.
The CEO of Sanofi admitted the pharmaceutical giant underperformed in emerging markets last year, after reporting a decline in quarterly sales.
The U.S.'s entire healthcare system needs to change, said Stefano Pessina, the non-executive director of Walgreens.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
Get the best of CNBC in your inbox